Patient characteristics and their association with OS
| Patient characteristics | Total (N=53) | Cox hazard model | ||
| HR | 95% CI | P value | ||
| Age (years), mean (SD) | 69.7 (8.5) | 1.23 | 0.88 to 1.74 | 0.232 |
| Sex, n (%) | ||||
| Female | 13 (25) | 1 | ||
| Male | 40 (75) | 0.92 | 0.44 to 1.92 | 0.826 |
| Smoking, n (%) | ||||
| Former | 40 (75) | 1 | ||
| Never | 13 (25) | 1.46 | 0.71 to 3.01 | 0.318 |
| Performance Status, n (%) | ||||
| 0–1 | 38 (71) | 1 | ||
| 2–3 | 15 (29) | 2.17 | 1.06 to 4.44 | 0.043 |
| Stage, n (%) | ||||
| Stage III (recurrent after chemoradiotherapy) | 7 (13) | 1 | ||
| Recurrent after surgery | 14 (26) | 2.25 | 0.47 to 10.72 | 0.308 |
| Stage IV | 32 (60) | 4.85 | 1.14 to 20.67 | 0.033 |
| Histology, n (%) | ||||
| Non-squamous | 38 (72) | 1 | ||
| Squamous | 15 (28) | 1.38 | 0.65 to 2.92 | 0.410 |
| Driver mutation, n (%) | ||||
| Wild Type | 41 (77) | 1 | ||
| EGFR (Epidermal growth factor receptor) | 11 (21) | 0.64 | 0.26 to 1.56 | 0.306 |
| ALK (Anaplastic lymphoma kinase) | 1 (2) | (EGFR or ALK/WT) | ||
| Tumor PD-L1 expression, n (%) | ||||
| 0%–49% | 21 (45) | |||
| 50%–100% | 26 (55) | 1.23 | 0.60 to 2.51 | 0.232 |
| Treatment line, n (%) | ||||
| 1st line | 20 (38) | 1 | ||
| 2nd line | 22 (42) | 0.76 | 0.36 to 1.60 | 0.471 |
| 3rd line | 7 (13) | 0.75 | 0.30 to 1.88 | 0.540 |
| 4th line | 2 (4) | (3rd line or later/1st line) | ||
| 6th and 7th lines | 2 (4) | |||
| PD-1 blocker, n (%) | ||||
| Nivolumab | 25 (47) | 1 | ||
| Pembrolizumab | 28 (53) | 1.37 | 0.70 to 2.66 | 0.358 |
| Blood test, mean (SD) | ||||
| Albumin (g/dL) | 3.42 (0.61) | 0.57 | 0.38 to 0.85 | 0.005 |
| LDH (lactate dehydrogenase, U/L) | 2634 (118) | 1.13 | 0.81 to 1.49 | 0.448 |
| White blood cell (/μL) | 7513 (3357) | 1.35 | 0.98 to 1.75 | 0.062 |
| Lymphocyte (/μL) | 1354 (615) | 0.58 | 0.38 to 0.86 | 0.006 |
| Neutrophil (/μL) | 5476 (2969) | 1.50 | 1.10 to 1.97 | 0.011 |
| Eosinophil (/μL) | 176 (178) | 0.80 | 0.52 to 1.15 | 0.248 |
| Monocyte (/μL) | 477 (223) | 1.49 | 1.05 to 2.02 | 0.027 |
| Neutrophil:lymphocyte ratio | 4.94 (3.56) | 1.72 | 1.27 to 2.25 | <0.001 |
Categorical variables are shown as the distribution of corresponding patient numbers. Continuous variables are shown as mean and SD values.
Univariate analysis was conducted using the Cox proportional hazard model for OS. HR, 95% CI.
ALK, anaplastic lymphoma kinase; LDH, lactate dehydrogenase; OS, overall survival; PS, performance status; WT, wild type.